UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials

Cancer, 2021-08, Vol.127 (15), p.2674-2682

2021

Volltextzugriff (PDF)

Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation

Human reproduction (Oxford), 2018-09, Vol.33 (9), p.1705-1714

2018

Volltextzugriff (PDF)

Everolimus

Small Molecules in Oncology, 2018, Vol.211, p.101-123

2018

Volltextzugriff (PDF)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Oncotarget, 2021-04, Vol.12 (8), p.859-872

2021

Volltextzugriff (PDF)

mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma

Current cancer drug targets, 2012-11, Vol.12 (9), p.1045-1061

2012

Volltextzugriff (PDF)

Design, development and in vitro quantification of novel electrosprayed everolimus-loaded Soluplus®/Polyvinyl alcohol nanoparticles via stability-indicating HPLC method in cancer therapy

European journal of pharmaceutics and biopharmaceutics, 2023-10, Vol.191, p.235-246

2023

Volltextzugriff (PDF)

Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors

Cancer, 2010-09, Vol.116 (18), p.4256-4265

2010

Volltextzugriff (PDF)

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

Neuro-oncology (Charlottesville, Va.), 2020-10, Vol.22 (10), p.1527-1535

2020

Volltextzugriff (PDF)

Ultrastructure and intercellular contact-mediated communication in cultured human early stage follicles exposed to mTORC1 inhibitor

Molecular human reproduction, 2019-11, Vol.25 (11), p.706-716

2019

Volltextzugriff (PDF)

RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma

Acta pharmaceutica Sinica. B, 2020-06, Vol.10 (6), p.1004-1019

2020

Volltextzugriff (PDF)

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

The Journal of neuroscience, 2008-05, Vol.28 (21), p.5422-5432

2008

Volltextzugriff (PDF)

Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL)

Cellular signalling, 2022-05, Vol.93, p.110301-110301, Article 110301

2022

Volltextzugriff (PDF)

Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology

The journals of gerontology. Series A, Biological sciences and medical sciences, 2018-06, Vol.73 (7), p.845-852

2018

Volltextzugriff (PDF)

A Novel Combination Therapy Approach Targeting STAT3 and Autophagy in Glioblastoma

Autophagy reports, 2022-12, Vol.1 (1), p.385-388

2022

Volltextzugriff (PDF)

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

Leukemia, 2014-04, Vol.28 (4), p.739-748

2014

Volltextzugriff (PDF)

Inhibition of the mTORC1 Pathway Suppresses Intestinal Polyp Formation and Reduces Mortality in $Apc^{\Delta 716}$ Mice

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (36), p.13544-13549

2008

Volltextzugriff (PDF)

STAT3 suppresses the AMPKα/ULK1‐dependent induction of autophagy in glioblastoma cells

Journal of cellular and molecular medicine, 2022-07, Vol.26 (14), p.3873-3890

2022

Volltextzugriff (PDF)

The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?

International journal of molecular sciences, 2018-03, Vol.19 (3), p.747

2018

Volltextzugriff (PDF)

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells

BMC cancer, 2016-07, Vol.16 (1), p.487-487, Article 487

2016

Volltextzugriff (PDF)

RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model

Clinical cancer research, 2007-07, Vol.13 (14), p.4261-4270

2007

Volltextzugriff (PDF)

RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial

Translational medicine of aging, 2020, Vol.4, p.32-34

Kaeberlein, Matt

2020

Volltextzugriff (PDF)

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

Cancer, 2009-06, Vol.115 (11), p.2438-2446

2009

Volltextzugriff (PDF)

The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas

Endocrine-related cancer, 2014-08, Vol.21 (4), p.R331-R344

2014

Volltextzugriff (PDF)

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

Pediatric blood & cancer, 2012-02, Vol.58 (2), p.173-180

2012

Volltextzugriff (PDF)

Self‐Assembled Antimitotic Peptide Vesicle Designed from α,β‐Tubulin Heterodimer Interface for Anticancer Drug Delivery

Israel journal of chemistry, 2022-10, Vol.62 (9-10), p.n/a

2022

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(177)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Rad001
(179)
Science & Technology
(173)
Life Sciences & Biomedicine
(171)
Humans
(142)
Everolimus
(129)
Oncology
(114)
Sirolimus - Analogs & Derivatives
(106)
Cell Line, Tumor
(70)
Mtor
(70)
Sirolimus - Pharmacology
(61)
Animals
(53)
Female
(50)
Biological And Medical Sciences
(49)
Medical Sciences
(48)
Tumors
(48)
Cell Proliferation - Drug Effects
(47)
Male
(45)
Tor Serine-Threonine Kinases - Antagonists & Inhibitors
(44)
Tor Serine-Threonine Kinases
(43)
Sirolimus - Therapeutic Use
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials

Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation

Everolimus

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma

Design, development and in vitro quantification of novel electrosprayed everolimus-loaded Soluplus®/Polyvinyl alcohol nanoparticles via stability-indicating HPLC method in cancer therapy

Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma: Final Results and Analysis of Prognostic Factors

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

Ultrastructure and intercellular contact-mediated communication in cultured human early stage follicles exposed to mTORC1 inhibitor

RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL)

Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology

A Novel Combination Therapy Approach Targeting STAT3 and Autophagy in Glioblastoma

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

Inhibition of the mTORC1 Pathway Suppresses Intestinal Polyp Formation and Reduces Mortality in $Apc^{\Delta 716}$ Mice

STAT3 suppresses the AMPKα/ULK1‐dependent induction of autophagy in glioblastoma cells

The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?

Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells

RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model

RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas

Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

Self‐Assembled Antimitotic Peptide Vesicle Designed from α,β‐Tubulin Heterodimer Interface for Anticancer Drug Delivery

Suchergebnisse filtern